EUVIMEDEUVIMED entdecken
Crossref

ADAMTS-13 fusion constructs with dual activity against von Willebrand factor: a novel strategy for immune-mediated thrombotic thrombocytopenic purpura

Yunpeng Xue, Mark Roest, Steven J Humphreys, Lisa N van der Vorm, Joke Konings, Piet Meijer, Claire S Whyte, Philip G de Groot, Nicholas A Arce, Renhao Li, Nicola J Mutch, Bas de Laat und 1 weitere

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.09.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Yunpeng Xue und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands; School for Cardiovascular Diseases, Cardiovascular Res…. Hauptthemen laut MEDLINE: ADAMTS13 Protein, von Willebrand Factor, Purpura, Thrombotic Thrombocytopenic, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: British Heart Foundation, National Heart Lung and Blood Institute Division of Intramural Research, Friends of ANCHOR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy. iTTP pathophysiology stems from severe a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS-13) deficiency caused by autoantibodies, leading to accumulation of ultralarge von Willebrand factor (VWF) multimers and microvascular thrombosis. Engineered ADAMTS-13 variants reduce autoantibody binding. However, some show impaired VWF-cleaving activity, whereas others, such as glycan-engineered variants, retain proteolytic function. OBJECTIVES: To investigate the AU/VWFa-11 (aVWF) single-domain antibody (sdAb) targeting the A1 domain of VWF in its active conformation, and 2 dual-action fusion constructs linking the sdAb to either a truncated ADAMTS-13 (Metalloprotease, Disintegrin, Thrombospondin type 1 repeat, Cysteine-rich and Spacer domains [MDTCS]; MDTCS-aVWF) or an autoantibody-resistant mutant (MDTCSm; MDTCSm-aVWF). METHODS: Binding of aVWF to active VWF and the VWF A1 domain was assessed by enzyme-linked immunosorbent assays. Proteolytic activity was assessed using fluorescence resonance energy transfer substrate (FRETS)-VWF73, VWF multimer, and beads-on-a-string assays. VWF-platelet interactions were measured by light transmission aggregometry and flow cytometry. Autoantibody resistance was evaluated using FRETS-VWF73 assays in the presence of plasma from iTTP patients. RESULTS: aVWF sdAb selectively bound active VWF and inhibited platelet-VWF interactions in solution without impairing platelet adhesion to collagen-bound VWF. Both MDTCS-aVWF and MDTCSm-aVWF retained high proteolytic activity against VWF and reduced platelet-VWF interactions. Notably, MDTCSm-aVWF showed enhanced proteolytic activity and greater resistance to iTTP autoantibodies. CONCLUSION: The fusion construct MDTCSm-aVWF, which combines an enzymatically active, autoantibody-resistant ADAMTS-13 variant with a VWF conformation-specific inhibitory sdAb, offers a novel alternative therapeutic approach for iTTP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAMTS13 Proteinvon Willebrand FactorPurpura, Thrombotic ThrombocytopenicRecombinant Fusion ProteinsSingle-Domain AntibodiesHumansAutoantibodiesProtein BindingProteolysisMutation

Stichwörter der Autor:innen

ADAMTS-13 proteinthrombotic thrombocytopenic purpuravon Willebrand factor

Substanzen

ADAMTS13 Proteinvon Willebrand FactorADAMTS13 protein, humanAutoantibodiesRecombinant Fusion ProteinsSingle-Domain Antibodies

Autor:innen und Institutionen

  • Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands; School for Cardiovascular Diseases, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maas…
  • Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands.
  • Aberdeen Cardiovascular & Diabetes Centre, Institute of Medical Sciences, School of Medicine, Medical Sciences, and Nutrition, University of Aberdeen, Aberdeen, United Kingdom.
  • Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands; Department of Clinical Chemistry and Hematology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands.
  • ECAT Foundation (External Quality Control for Assays and Tests), Voorschoten, The Netherlands.
  • Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, USA; Division of Oncology Biologics, Eli Lilly and Company, Sou…

Förderung

  • British Heart Foundation
  • National Heart Lung and Blood Institute Division of Intramural Research
  • Friends of ANCHOR
  • China Scholarship Council
  • National Centre for the Replacement Refinement & Reduction of Animals in Research

Zitieren

APA

Xue, Y., Roest, M., Humphreys, S. J., van der Vorm, L. N., Konings, J., Meijer, P., Whyte, C. S., de Groot, P. G., Arce, N. A., Li, R., Mutch, N. J., de Laat, B., & Huskens, D. (2026). ADAMTS-13 fusion constructs with dual activity against von Willebrand factor: a novel strategy for immune-mediated thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.09.002

Vancouver

Xue Y, Roest M, Humphreys SJ, van der Vorm LN, Konings J, Meijer P, et al. ADAMTS-13 fusion constructs with dual activity against von Willebrand factor: a novel strategy for immune-mediated thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.09.002

BibTeX
@article{Xue2026,
  author = {Xue, Yunpeng and Roest, Mark and Humphreys, Steven J and van der Vorm, Lisa N and Konings, Joke and Meijer, Piet and Whyte, Claire S and de Groot, Philip G and Arce, Nicholas A and Li, Renhao and Mutch, Nicola J and de Laat, Bas and Huskens, Dana},
  title = {ADAMTS-13 fusion constructs with dual activity against von Willebrand factor: a novel strategy for immune-mediated thrombotic thrombocytopenic purpura},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.09.002}
}
Kostenlos starten →